Mario Sznol, MD
Combination regimens continue to push the field of melanoma further, following the success that has been seen with nivolumab (Opdivo) and ipilimumab (Yervoy), according to Mario Sznol, MD.
on Melanoma, Sznol discussed overall advances in the field of melanoma, as well as novel treatments with the potential to change the treatment paradigm.
OncLive: What exciting advancements have we recently seen in the field of melanoma?
Currently, the SOC is either single-agent anti–PD-1 or the combination of ipilimumab and nivolumab. In the future, it could involve different combinations, mostly centered around anti–PD-1. Those potential combinations are being studied in many ongoing phase III trials. We will be discussing the design of those studies and the new agents that might be approved within the next 1 or 2 years for the treatment of metastatic melanoma.
... to read the full story